Ovarian Cancer

Laurie H. Glimcher, MD, discusses the promise of XBP1 inhibition as an immunotherapy strategy in ovarian cancer.

Saeed Rafii, MD, PhD, MRCP, medical director, Sarah Cannon Research Institute, discusses factors that influence clinical outcomes to olaparib in patients with BRCA1/2-mutant ovarian cancer.

A retrospective analysis of the phase III GOG-0218 trial has identified a potential biomarker of response for bevacizumab in patients with advanced ovarian cancer.

Treatment with the PARP inhibitor rucaparib demonstrated robust clinical activity and a tolerable safety profile for women with biomarker-defined relapsed ovarian cancer

Monoclonal antibodies against PD-1 and PD-L1 have demonstrated encouraging signs of antitumor activity for patients with pretreated advanced ovarian cancer.

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, discusses how bevacizumab could be effective in tumor types beyond ovarian cancer.

Optimal testing strategies for breast and ovarian cancer associated with mutations in the BRCA1/2 genes, including when to start testing and which prophylactic approach to pursue, have remained a topic of debate.

Joanne Xiu, PhD, research scientist, Caris Life Sciences, discusses findings from a study that showed hormone receptor (HR) expression is present in a subset of patients with uterine carcinosarcoma.

In an interview with OncLive, Robert C. Bast, Jr, MD, discussed his research using CA-125 levels and p53-autoantibodies as biomarkers for early detection of ovarian cancer.

Robert C. Bast, Jr., MD, vice president, Translational Research, The University of Texas MD Anderson Cancer Center, discusses a study that could help in early detection of ovarian cancer before CA-125 rises in patients.

The combination of olaparib with the novel AKT-targeting agent AZD5363 generated responses in a variety of tumor types among patients with and without BRCA1/2 mutations, demonstrating that a simultaneous attack on the two pathways is a safe and potentially versatile strategy.

A two-pronged strategy combining the PARP inhibitor olaparib and the PI3K inhibitor BKM120 proved to be a safe and clinically beneficial regimen for women with triple-negative breast cancer and for patients with high-grade serous ovarian cancer.

Clinical trial evidence indicates that some women with high-grade serous ovarian cancer who do not test positive for a BRCA mutation also may respond to olaparib.

Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.

Ursula A. Matulonis, MD, medical director, gynecologic oncology, Susan F. Smith Center for Women's Cancers, institute physician, Dana-Farber Cancer Institute, discusses managing toxicities associated with olaparib for patients with ovarian cancer.

The FDA has granted a breakthrough therapy designation to rucaparib as a treatment for women with BRCA-mutated advanced ovarian cancer who have received at least two prior lines of platinum-based chemotherapy.

Fosbretabulin plus bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in patients with recurrent ovarian cancer.

Treatment with bevacizumab plus a chemotherapy doublet extended overall survival by nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage III/IV ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not in an open-label phase II trial.